Navigating First-Line Therapy Options in Metastatic Pancreatic Adenocarcinoma
Sreenivasa Chandana, MD, PhD and Darshil Shah, MD, MPH discuss how different first-line treatment options for metastatic pancreatic adenocarcinoma (including FOLFIRINOX, gemcitabine/nab-paclitaxel, and the newer NALIRIFOX regimen) compare in efficacy and toxicity profiles, emphasizing the importance of patient-specific factors in treatment selection and noting that dose reductions may actually improve survival by allowing patients to remain on therapy longer.
EP. 1: First-Line Treatment Options for Metastatic Pancreatic Adenocarcinoma
May 28th 2025Panelists discuss how the current first-line treatment landscape for metastatic pancreatic adenocarcinoma includes NCCN-recommended regimens like FOLFIRINOX, gemcitabine plus nab-paclitaxel, and the newest addition NALIRIFOX, with treatment selection guided by toxicity profiles, patient-specific factors, and the importance of germline testing.
EP. 2: Insights From The NAPOLI-3 and PRODIGE4 Trials In Metastatic Pancreatic Adenocarcinoma
May 28th 2025Panelists discuss how the NAPOLI-3 trial led to FDA approval of NALIRIFOX after demonstrating superior median overall survival (11.1 months) and progression-free survival (7.4 months) compared to gemcitabine/nab-paclitaxel, with key differences from the older PRODIGE 4 study including a lower oxaliplatin dose that may reduce side effects.
EP. 3: Managing AEs Associated With the FOLFIRINOX and NALIRIFOX Regimens in Pancreatic Cancer
May 29th 2025Panelists discuss how adverse event profiles differ between regimens—with FOLFIRINOX causing high rates of neutropenia and neuropathy while NALIRIFOX shows lower neuropathy rates but higher grade 3 diarrhea—making patient-specific factors crucial for treatment selection and emphasizing the importance of dose adjustments and patient education.
EP. 4: NAPOLI-3 in Real World Practice: Expert Insights on Data From ASCO GI 2025
May 29th 2025Panelists discuss how real-world retrospective data from the Flatiron Health Database showed median overall survival of approximately 9 months for FOLFIRINOX-treated patients, which appears numerically lower than NALIRIFOX results, though these findings require cautious interpretation due to the non-randomized nature of the comparison.
EP. 5: Evaluating the Impact Of UGT1A1*28 Status On Tolerability Of NALIRIFOX In mPDAC
May 29th 2025Panelists discuss how UGT1A1 mutations may predict increased diarrhea risk in patients receiving NALIRIFOX, with genetic testing potentially valuable for identifying patients who need more aggressive supportive care or dose modifications, particularly those with borderline performance status.
EP. 6: NALIRIFOX In Practice: Treatment Strategies for Patients With mPDAC
May 29th 2025Panelists discuss how dose reductions in the NAPOLI-3 trial paradoxically led to improved survival outcomes (12.6 months for nanoliposomal irinotecan reductions and 13.5 months for oxaliplatin reductions versus shorter survival with full doses), supporting their clinical approach of maintaining patients on tolerable doses for longer treatment duration rather than pursuing maximum dose intensity.
